Observational studyJournal of cardiovascular electrophysiology2026
Stroke and Bleeding Risks in Atrial Fibrillation Are Not Static but Dynamic: A Dynamic Assessment of CHA
Observational study in Journal of cardiovascular electrophysiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Stroke and Bleeding Risks in Atrial Fibrillation Are Not Static but Dynamic: A Dynamic Assessment of CHAJournal of cardiovascular electrophysiology · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
BACKGROUND AND
objectivesProper stroke and bleeding risk assessment is an essential part of clinical decision-making in patients with atrial fibrillation (AF). This study aims to determine whether the dynamic assessment of CHA
methodsIn this prospective longitudinal study-based on data from the Iranian Atrial Fibrillation Registry (IRAF)-patients with available CHA₂DS₂-VASc and HAS-BLED scores at baseline, first follow-up (after 6 months), and second follow-up (after 12 months) were included. Univariable and multivariable logistic regression analyses were performed to evaluate the association of CHA₂DS₂-VASc and HAS-BLED scores (i.e., scores at baseline, first follow-up, and their difference defined as delta) with stroke and bleeding risk, respectively.
resultsA total of 529 patients (mean age 61.2 ± 14.3 years; 59.7% male) were included. CHA₂DS₂-VASc and HAS-BLED scores increased significantly after 6 and 12 months from recruitment. delta CHA₂DS₂-VASc score (AUC 0.69; 95% CI: 0.54-0.84) and First follow-up CHA₂DS₂-VASc score (AUC 0.70; 95% CI: 0.51-0.88) achieved higher AUCs compared to baseline CHA₂DS₂-VASc score (AUC 0.63; 95% CI: 0.44-0.82). delta HAS-BLED score had the highest AUC (AUC 0.73; 95% CI: 0.55-0.91) compared to baseline (AUC 0.58; 95% CI: 0.43-0.74) and first follow-up HAS-BLED (AUC 0.60; 95% CI: 0.44-0.80) scores.
conclusionsRegular reassessment of CHA₂DS₂-VASc and HAS-BLED scores is essential in AF patients, as stroke and bleeding risks change over time, emphasizing the need for dynamic risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.